Edward Nirenberg on Nostr: Regarding maternal vaccination- there is no issue with supply vs. demand here. ...
Regarding maternal vaccination- there is no issue with supply vs. demand here. Nirsevimab however is tougher. To help reduce costs, more birthing facilities are being enrolled in the VFC program to get nirsevimab.
Published at
2024-06-28 14:49:09Event JSON
{
"id": "422d3cc53fa231c2ce7818c6b5343a5b7cedeaa09b29c55c0110c43354fd35e3",
"pubkey": "c67b38e4c5023e985f04ae7ab6a6669cf463220e1b9ed54b897d1957004603a4",
"created_at": 1719586149,
"kind": 1,
"tags": [
[
"e",
"0584a28f87dab19cfcb930025286b45f7fb28005e495e0cb20866dd3d4c072c9",
"wss://relay.mostr.pub",
"reply"
],
[
"proxy",
"https://med-mastodon.com/users/enirenberg/statuses/112694797906556712",
"activitypub"
]
],
"content": "Regarding maternal vaccination- there is no issue with supply vs. demand here. Nirsevimab however is tougher. To help reduce costs, more birthing facilities are being enrolled in the VFC program to get nirsevimab.\n\nhttps://cdn.masto.host/medmastodoncom/media_attachments/files/112/694/797/802/622/560/original/d626af30007f5663.png\n\nhttps://cdn.masto.host/medmastodoncom/media_attachments/files/112/694/797/769/216/977/original/c0ff5d9739a46a1a.png",
"sig": "57d1acfeb4f962e9862275bfca3d531baba32ccb443708207a1ce99a64dc00c3bc36f1ff43f1153ddd592a0e0ca9ec738f817bea61baab1fd1e67b7743f45eb0"
}
